“Decrease in migraine frequency” followed by “decrease in migraine severity” were the top priority outcomes for stakeholders in migraine medications; this understanding will help inform value-based contracts between patients and industry.
Why this matters
Migraine is a common neurological problem which causes significant disability.
Treatment options for migraine have expanded in the past few years, with the introduction of novel anti-migraine therapies including monoclonal antibodies; however, these novel agents are very expensive, and their real-world value is yet to be fully demonstrated.
Value-based contracts work by linking medication costs to predefined, real-world performance metrics to help ensure that incentives are aligned and risk is shared between payers and drug manufacturers; in this way, patient medication costs are limited by the measurable value they receive from their medication, with the additional costs covered by the manufacturers.
It is unclear which are the most meaningful outcome measures for stakeholders, including patients, employers, payers, providers, and industry, regarding migraine medications.